In summary, our analysis of the pre-clinical efficacy of TM inhibitors of PAI-1 brings important and novel information on their activity in cancer, but also tolerability that should be helpful in the future design of more effective inhibitors. This evidence concerns the gene SERPINE1 and cancer.